```
=> d his ful

     (FILE 'HOME' ENTERED AT 13:13:36 ON 12 FEB 2006)

     FILE 'HCAPLUS' ENTERED AT 13:13:41 ON 12 FEB 2006
                E BENAVIDES JESUS/AU
L1           82 SEA ABB=ON  "BENAVIDES JESUS"/AU
                E BOCCIO DANIEL/AU
                E DANIEL BOCCIO FAY P/AU
                E DANIEL BOCCIO, FAY P/AU
                E BOCCIO DANIEL/AU
L2            4 SEA ABB=ON  ("BOCCIO D"/AU OR "BOCCIO DANIEL"/AU)
                E HENIN YVETTE/AU
L3           32 SEA ABB=ON  ("HENIN Y"/AU OR "HENIN YVETTE"/AU)
                E PIOT GROSJEAN ODILE/AU
L4            4 SEA ABB=ON  "PIOT GROSJEAN ODILE"/AU
L5            2 SEA ABB=ON  L1 AND L2 AND L3 AND L4
                SELECT RN L5 1-1

     FILE 'REGISTRY' ENTERED AT 13:16:24 ON 12 FEB 2006
L6           44 SEA ABB=ON  (57308-51-7/BI OR 101626-70-4/BI OR 104632-26-0/BI
                OR 106-89-8/BI OR 124-63-0/BI OR 130929-57-6/BI OR 134308-13-7/
                BI OR 136236-51-6/BI OR 14611-51-9/BI OR 155210-57-4/BI OR
                158681-13-1/BI OR 171752-56-0/BI OR 179386-44-8/BI OR 25614-03-
                3/BI OR 261924-66-7/BI OR 358970-91-9/BI OR 358970-92-0/BI OR
                358970-97-5/BI OR 358971-48-9/BI OR 372-39-4/BI OR 499771-49-2/
                BI OR 499771-50-5/BI OR 499771-51-6/BI OR 499771-52-7/BI OR
                499771-53-8/BI OR 499771-54-9/BI OR 499771-55-0/BI OR 499771-56
                -1/BI OR 499771-57-2/BI OR 499771-58-3/BI OR 499771-59-4/BI OR
                499771-60-7/BI OR 499771-61-8/BI OR 500019-91-0/BI OR 500019-92
                -1/BI OR 503-29-7/BI OR 5267-41-4/BI OR 58-96-8/BI OR 59-92-7/B
                I OR 7101-51-1/BI OR 80373-22-4/BI OR 81409-90-7/BI OR
                91374-21-9/BI OR 99755-59-6/BI)

     FILE 'HCAPLUS' ENTERED AT 13:16:33 ON 12 FEB 2006
L7            2 SEA ABB=ON  L5 AND L6
L8              ANALYZE L7 1 CT :       8 TERMS

     FILE 'REGISTRY' ENTERED AT 13:20:49 ON 12 FEB 2006
L9            1 SEA ABB=ON  LEVODOPA/CN
L10           1 SEA ABB=ON  358970-97-5/RN  RN of requested compd ② identified from Inventor search

     FILE 'HCAPLUS' ENTERED AT 13:21:12 ON 12 FEB 2006
L11           1 SEA ABB=ON  (L9 OR ?LEVODOPA?) AND L10  1 cit from CA Plus

     FILE 'USPATFULL' ENTERED AT 13:21:46 ON 12 FEB 2006
L12           1 SEA ABB=ON  (L9 OR ?LEVODOPA?) AND L10  1 cit from USPatFull

     FILE HOME

     FILE HCAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     the American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storing
```

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Feb 2006 VOL 144 ISS 8
FILE LAST UPDATED: 10 Feb 2006 (20060210/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 10 FEB 2006 HIGHEST RN 874099-70-4
DICTIONARY FILE UPDATES: 10 FEB 2006 HIGHEST RN 874099-70-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from  *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 9 Feb 2006 (20060209/PD)
FILE LAST UPDATED: 9 Feb 2006 (20060209/ED)
HIGHEST GRANTED PATENT NUMBER: US6996845
HIGHEST APPLICATION PUBLICATION NUMBER: US2006031974
CA INDEXING IS CURRENT THROUGH 9 Feb 2006 (20060209/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 9 Feb 2006 (20060209/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

```
=> d que stat l11
L9            1 SEA FILE=REGISTRY ABB=ON  LEVODOPA/CN
L10           1 SEA FILE=REGISTRY ABB=ON  358970-97-5/RN
L11           1 SEA FILE=HCAPLUS ABB=ON  (L9 OR ?LEVODOPA?) AND L10

=> d ibib abs hitstr l11 1-1

L11  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:197162  HCAPLUS
DOCUMENT NUMBER:          138:198654
TITLE:                    combination of a CB1 receptor antagonist and a brain
                          dopaminergic neurotransmission activator,
                          pharmaceutical compositions containing them, and their
                          use in the treatment of Parkinson's disease
INVENTOR(S):              Benavides, Jesus; Boccio, Daniel; Henin, Yvette; Piot,
                          Grosjean Odile
PATENT ASSIGNEE(S):       Aventis Pharma SA, Fr.
SOURCE:                   Fr. Demande, 96 pp.
                          CODEN: FRXXBL
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     FR 2829028            A1    20030307    FR 2001-11200            20010829
     FR 2829028            B1    20041217
     CA 2458348            AA    20030313    CA 2002-2458348          20020828
     WO 2003020314         A1    20030313    WO 2002-FR2946           20020828
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     EP 1423145            A1    20040602    EP 2002-772514           20020828
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     JP 2005505551         T2    20050224    JP 2003-524621           20020828
     US 2004209861         A1    20041021    US 2004-786810           20040225
PRIORITY APPLN. INFO.:                       FR 2001-11200        A   20010829
                                             WO 2002-FR2946       W   20020828

OTHER SOURCE(S):          MARPAT 138:198654
AB   The invention discloses the combination of one or more azetidine derivative
     CB1 antagonists and one or more substances which activate dopaminergic
     neurotransmission in the brain, as well as pharmaceutical compns. containing
     them and their use for the treatment of Parkinson's disease.  Methods for
     azetidine derivative preparation are described.
IT   358970-97-5P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
        (dopaminergic neurotransmission activator-CB1 receptor antagonist
        combination, pharmaceutical compns., and use in Parkinson's disease
        treatment)
```

RN 358970-97-5 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **59-92-7, Levodopa**, biological studies
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 59-92-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> d que stat l12
L9            1 SEA FILE=REGISTRY ABB=ON  LEVODOPA/CN
L10           1 SEA FILE=REGISTRY ABB=ON  358970-97-5/RN
L12           1 SEA FILE=USPATFULL ABB=ON  (L9 OR ?LEVODOPA?) AND L10


=> d ibib abs hitstr l12 1-1

L12  ANSWER 1 OF 1  USPATFULL on STN
ACCESSION NUMBER:        2004:268318  USPATFULL
TITLE:                   Combination of a CB1 receptor antagonist and of a
                         product which activatives dopaminergic
                         neurotransmission in the brain, the pharmaceutical
                         compositions comprising them and their use in the
                         treatment of parkinson's disease
INVENTOR(S):             Benavides, Jesus, Chatenay Malabry, FRANCE
                         Boccio, Daniel, Fay P. Bippov, FRANCE
                         Henin, Yvette, Paris, FRANCE
                         Piot-Grosjean, Odile, Choisy Le Roi, FRANCE
                         Henin, Paris, FRANCE
PATENT ASSIGNEE(S):      Aventis Pharma S.A., Cedex, FRANCE (non-U.S.
                         corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2004209861      A1   20041021
APPLICATION INFO.:       US 2004-786810     A1   20040225  (10)
RELATED APPLN. INFO.:    Continuation of Ser. No. WO 2002-FR2946, filed on 28
                         Aug 2002, UNKNOWN

                                NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    FR 2001-11200      20010829
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE
                         202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS:        36
EXEMPLARY CLAIM:         1
LINE COUNT:              2468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to the combination of one or more CB1
       antagonist azetidine derivatives and of one or more products which
       activate dopaminergic neurotransmission in the brain, to the
       pharmaceutical compositions comprising them and to their use in the
       treatment of Parkinson's disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT   358970-97-5P
       (dopaminergic neurotransmission activator-CB1 receptor antagonist
       combination, pharmaceutical compns., and use in Parkinson's disease
       treatment)
RN   358970-97-5  USPATFULL
CN   Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-
       difluorophenyl)- (9CI)  (CA INDEX NAME)
```



IT **59-92-7**, Levodopa, biological studies
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 59-92-7 USPATFULL
CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Inventor Search

=> d ibib abs hitstr l7 1-2

L7 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:197162 HCAPLUS
DOCUMENT NUMBER: 138:198654
TITLE: combination of a CB1 receptor antagonist and a brain dopaminergic neurotransmission activator, pharmaceutical compositions containing them, and their use in the treatment of Parkinson's disease
INVENTOR(S): **Benavides, Jesus; Boccio, Daniel; Henin, Yvette; Piot, Grosjean Odile**
PATENT ASSIGNEE(S): Aventis Pharma SA, Fr.
SOURCE: Fr. Demande, 96 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2829028	A1	20030307	FR 2001-11200	20010829
FR 2829028	B1	20041217		
CA 2458348	AA	20030313	CA 2002-2458348	20020828
WO 2003020314	A1	20030313	WO 2002-FR2946	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1423145	A1	20040602	EP 2002-772514	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505551	T2	20050224	JP 2003-524621	20020828
US 2004209861	A1	20041021	US 2004-786810	20040225
PRIORITY APPLN. INFO.:			FR 2001-11200 A	20010829
			WO 2002-FR2946 W	20020828

OTHER SOURCE(S): MARPAT 138:198654

AB The invention discloses the combination of one or more azetidine derivative CB1 antagonists and one or more substances which activate dopaminergic neurotransmission in the brain, as well as pharmaceutical compns. containing them and their use for the treatment of Parkinson's disease. Methods for azetidine derivative preparation are described.

IT **80373-22-4**, Quinpirole **158681-13-1**, SR141716A
RL: PAC (Pharmacological activity); BIOL (Biological study)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 80373-22-4 HCAPLUS
CN 1H-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 158681-13-1 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT **358970-91-9P 358970-97-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 358970-91-9 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 358970-97-5 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



IT **58-96-8**, Uridine **59-92-7**, Levodopa, biological studies
503-29-7D, Azetidine, derivs. **7101-51-1**, CHF 1301
14611-51-9, Selegiline **25614-03-3**, Bromocriptine
57308-51-7, Duodopa **81409-90-7**, Cabergoline
91374-21-9, Ropinirole **99755-59-6**, Rotigotine
101626-70-4, Talipexole **104632-26-0**, Pramipexole
130929-57-6, Entacapone **134308-13-7**, Tolcapone
136236-51-6, Rasagiline **155210-57-4**, BAM-1110
171752-56-0, Adrogolide **179386-44-8**, PNU-95666
499771-49-2 **499771-50-5** **499771-51-6**
499771-52-7 **499771-53-8** **499771-54-9**
499771-55-0 **499771-56-1** **499771-57-2**
499771-58-3 **499771-59-4** **499771-60-7**
500019-91-0, TV 1203 **500019-92-1**, SL 340026
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)

RN 58-96-8 HCAPLUS
CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 59-92-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503-29-7 HCAPLUS
CN Azetidine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

RN 7101-51-1 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 14611-51-9 HCAPLUS
CN Benzeneethanamine, N,α-dimethyl-N-2-propynyl-, (αR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 25614-03-3 HCAPLUS
CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 57308-51-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, mixt. with (αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 28860-95-9
CMF C10 H14 N2 O4

Absolute stereochemistry.



CM 2

CRN 59-92-7
CMF C9 H11 N O4

Absolute stereochemistry.



RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 91374-21-9 HCAPLUS
CN 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 99755-59-6 HCAPLUS
CN 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 101626-70-4 HCAPLUS
CN 4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 104632-26-0 HCAPLUS
CN 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 130929-57-6 HCAPLUS
CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 134308-13-7 HCAPLUS
CN Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 136236-51-6 HCAPLUS
CN 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 155210-57-4 HCAPLUS
CN Ergoline, 6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 105579-47-3
CMF C18 H21 N5

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 171752-56-0 HCAPLUS
CN Benzo[f]thieno[2,3-c]quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), (5aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179386-44-8 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179386-43-7
CMF C11 H13 N3 O

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 499771-49-2 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 59-92-7
CMF C9 H11 N O4

Absolute stereochemistry.



RN 499771-50-5 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinyl-, mixt. with 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 91374-21-9
CMF C16 H24 N2 O



RN 499771-51-6 HCAPLUS
CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 25614-03-3
CMF C32 H40 Br N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 499771-52-7 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinyl-, mixt. with (6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 104632-26-0
CMF C10 H17 N3 S

Absolute stereochemistry. Rotation (-).



RN 499771-53-8 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-

pyridinyl-, mixt. with (1R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 136236-51-6
CMF C12 H13 N

Absolute stereochemistry. Rotation (+).



RN 499771-54-9 HCAPLUS
CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-3-pyridinylmethanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-91-9
CMF C22 H21 Cl2 N3 O2 S



CM 2

CRN 130929-57-6
CMF C14 H15 N3 O5

Double bond geometry as shown.



RN 499771-55-0 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 59-92-7
CMF C9 H11 N O4

Absolute stereochemistry.



RN 499771-56-1 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-, mixt. with 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 91374-21-9
CMF C16 H24 N2 O



RN 499771-57-2 HCAPLUS
CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 25614-03-3
CMF C32 H40 Br N5 O5

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 499771-58-3 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-, mixt. with (6S)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazolediamine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 104632-26-0
CMF C10 H17 N3 S

Absolute stereochemistry. Rotation (-).



RN 499771-59-4 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)-, mixt. with (1R)-2,3-dihydro-N-2-propynyl-1H-inden-1-amine (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 136236-51-6
CMF C12 H13 N

Absolute stereochemistry. Rotation (+).



RN 499771-60-7 HCAPLUS
CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-, mixt. with N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(3,5-difluorophenyl)methanesulfonamide (9CI) (CA INDEX NAME)

CM 1

CRN 358970-97-5
CMF C23 H20 Cl2 F2 N2 O2 S



CM 2

CRN 130929-57-6
CMF C14 H15 N3 O5

Double bond geometry as shown.



RN 500019-91-0 HCAPLUS
CN TV 1203 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500019-92-1 HCAPLUS
CN SL 340026 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **106-89-8**, reactions **124-63-0**, Methylsulfonyl chloride
372-39-4, 3,5-Difluoroaniline **5267-41-4**
358970-92-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 106-89-8 HCAPLUS
CN Oxirane, (chloromethyl)- (9CI) (CA INDEX NAME)



RN 124-63-0 HCAPLUS
CN Methanesulfonyl chloride (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 372-39-4 HCAPLUS
CN Benzenamine, 3,5-difluoro- (9CI) (CA INDEX NAME)



RN 5267-41-4 HCAPLUS
CN Benzenemethanamine, 4-chloro-α-(4-chlorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 358970-92-0 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]-N-(1-oxido-3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **261924-66-7P 358971-48-9P 499771-61-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(dopaminergic neurotransmission activator-CB1 receptor antagonist combination, pharmaceutical compns., and use in Parkinson's disease treatment)
RN 261924-66-7 HCAPLUS
CN 3-Azetidinol, 1-[bis(4-chlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 358971-48-9 HCAPLUS
CN Methanesulfonamide, N-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 499771-61-8 HCAPLUS
CN Methanesulfonamide, N-[1-[bis(4-chlorophenyl)methyl]-3-azetidinyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:173468 HCAPLUS
DOCUMENT NUMBER: 138:198652
TITLE: Composition for treating Parkinson's disease containing a CB1 receptor antagonist and an agent activating dopaminergic neurotransmission in the brain
INVENTOR(S): **Benavides, Jesus; Boccio, Daniel; Henin, Yvette; Piot-Grosjean, Odile**
PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018060	A1	20030306	WO 2002-FR2945	20020828
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2829027	A1	20030307	FR 2001-11201	20010829
CA 2458855	AA	20030306	CA 2002-2458855	20020828
EP 1423146	A1	20040602	EP 2002-774886	20020828
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005505539	T2	20050224	JP 2003-522575	20020828
US 2005107356	A1	20050519	US 2004-786483	20040225
PRIORITY APPLN. INFO.:			FR 2001-11201 A	20010829
			WO 2002-FR2945 W	20020828

OTHER SOURCE(S): MARPAT 138:198652

AB The invention discloses a combination of one or several azetidine derivative CB1 antagonists and one or several agents activating dopaminergic neurotransmission in the brain, as well as pharmaceutical compns. containing them and their use for treating Parkinson's disease.

IT **58-96-8**, Uridine **59-92-7**, Levodopa, biological studies
503-29-7D, Azetidine, derivs. **14611-51-9**, Selegiline
25614-03-3, Bromocriptine **57308-51-7**, CHF 1512
80373-22-4, Quinpirole **81409-90-7**, Cabergoline
91374-21-9, Ropinirole **99755-59-6**, Rotigotine
104632-26-0, Pramipexole **130929-57-6**, Entacapone
134308-13-7, Tolcapone **136236-51-6**, Rasagiline
155210-57-4, BAM-1110 **158681-13-1**, SR141716A
171752-56-0, Adrogolide **179386-44-8**, PNU-95666
500019-91-0, TV 1203 **500019-92-1**, SL 340026
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CB1 receptor antagonist combination with agent activating dopaminergic neurotransmission in brain for treating Parkinson's disease)

RN 58-96-8 HCAPLUS
CN Uridine (8CI, 9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 59-92-7 HCAPLUS

CN L-Tyrosine, 3-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 503-29-7 HCAPLUS
CN Azetidine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)

RN 14611-51-9 HCAPLUS
CN Benzeneethanamine, N,α-dimethyl-N-2-propynyl-, (αR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 25614-03-3 HCAPLUS
CN Ergotaman-3',6',18-trione, 2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'α)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 57308-51-7 HCAPLUS
CN L-Tyrosine, 3-hydroxy-, mixt. with (αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 28860-95-9
CMF C10 H14 N2 O4

Absolute stereochemistry.



CM 2

CRN 59-92-7
CMF C9 H11 N O4

Absolute stereochemistry.



RN 80373-22-4 HCAPLUS
CN 1H-Pyrazolo[3,4-g]quinoline, 4,4a,5,6,7,8,8a,9-octahydro-5-propyl-, (4aR,8aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 81409-90-7 HCAPLUS
CN Ergoline-8-carboxamide, N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8β)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 91374-21-9 HCAPLUS
CN 2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 99755-59-6 HCAPLUS
CN 1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 104632-26-0 HCAPLUS
CN 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 130929-57-6 HCAPLUS
CN 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 134308-13-7 HCAPLUS
CN Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 136236-51-6 HCAPLUS
CN 1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (1R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 155210-57-4 HCAPLUS
CN Ergoline, 6-methyl-8-(1H-1,2,4-triazol-1-ylmethyl)-, (8β)-, (2Z)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 105579-47-3
CMF C18 H21 N5

Absolute stereochemistry.



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 158681-13-1 HCAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171752-56-0 HCAPLUS
CN Benzo[f]thieno[2,3-c]quinoline-9,10-diol, 4,5,5a,6,7,11b-hexahydro-2-propyl-, diacetate (ester), (5aR-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 179386-44-8 HCAPLUS
CN 4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 179386-43-7
CMF C11 H13 N3 O

Absolute stereochemistry. Rotation (-).



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 500019-91-0 HCAPLUS
CN TV 1203 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 500019-92-1 HCAPLUS
CN SL 340026 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT